Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma

International Journal of Hematology

Volumn 88, Issue 4, 2008, Pages 434-440

  Weisel, Katja C ^a   Weidmann, Eckhart ^b   Anagnostopoulos, Ioannis ^c   Kanz, Lothar ^a   Pezzutto, Antonio ^c   Subklewe, Marion ^c  

^a Medizinische Klinik IV   (Germany)

^b KRANKENHAUS NORDWEST   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

AILT; Alemtuzumab; Epstein Barr virus; Fludarabine; Peripheral T cell lymphoma; Secondary B cell lymphoma

Indexed keywords

ALEMTUZUMAB; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; GANCICLOVIR; PREDNISONE; RITUXIMAB; TUBERCULOSTATIC AGENT; VINCRISTINE; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CYTARABINE; MONOCLONAL ANTIBODY;

ADULT; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; DEATH; EPIGASTRIC PAIN; EPSTEIN BARR VIRUS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; LUNG NODULE; LYMPH NODE; MALE; MILIARY TUBERCULOSIS; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PERIPHERAL T CELL LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; RETINITIS; SWELLING; T CELL LYMPHOMA; VIRUS LATENCY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; LARGE CELL LYMPHOMA; MIDDLE AGED; PATHOLOGY; SECOND CANCER; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; VIRUS LATENCY;

EID: 64249135477     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0176-2     Document Type: Article

References (39)

1. S Louie PR Daoust RS Schwartz 1980 Immunodeficiency and the pathogenesis of non-Hodgkin's lymphoma Semin Oncol. 7 267 84
2. JF Buell TG Gross ES Woodle 2005 Malignancy after transplantation Transplantation 80 Suppl2 S254 64 10.1097/01.tp.0000186382.81130.ba
3. AB Rickinson DJ Moss 1997 Human cytotoxic T lymphocyte responses to Ebstein-Barr virus infection Annu Rev Immunol. 15 405 31 10.1146/annurev. immunol.15.1.405
4. G Pizzolo F Vinante C Agostini R Zambello L Trentin M Masciarelli 1987 Immunologic abnormalities in angioimmunoblastic lymphadenopathy Cancer. 60 2412 8 10.1002/1097-0142(19871115)60:10<2412::AID-CNCR2820601010>3.0.CO;2-F
5. A Zettl SS Lee T Rüdiger P Starostik M Marino T Kirchner 2002 Ebstein-Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified M J Clin Pathol. 117 368 79 10.1309/6UTX-GVC0-12ND-JJEU
6. I Anagnostopoulos M Hummel T Finn M Tiemann P Korbjuhn C Dimmler 1992 Heterogenous Ebstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type Blood. 80 1804 12
7. LM Weiss ES Jaffe XF Liu YY Chen D Shibata LJ Medeiros 1992 Detection and localization of Ebstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma Blood. 79 1789 95
8. K Willenbrock A Brauninger ML Hansmann 2007 Frequent occurrence of B-cell lymphomas in angioummunoblastic T-cell lymphoma and proliferation of Ebstein-Barr virus-infected cells in early cases Br J Haematol. 138 733 9 10.1111/j.1365-2141.2007.06725.x
9. W Siegert A Agthe H Griesser R Schwedtfeger G Brittinger M Engelhard 1992 Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group Ann Intern Med. 117 364 70
10. SI Martin FM Marty K Fiumara SP Treon JG Gribben LR Baden 2006 Infectious complications associated with alemtuzumab use for lymphoproliferative disorders Clin Infect Dis. 43 16 24 10.1086/504811
11. R Kurzrock F Ravandi 2006 Purine analogues in advanced T-cell lymphoid malignancies Semin Hematol 43Suppl 2 2 S27 34 10.1053/j.seminhematol.2005.12.010
12. N Yawalkar K Ferenczi DA Jones K Yamanaka KY Suh S Sadat 2003 Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma Blood. 102 4059 66 10.1182/blood-2003-04-1044
13. K Yamanaka N Yawalkar DA Jones D Hurwitz K Ferenczi S Eapen 2005 Decreased T-cell receptor excision circles in cutaneous T-cell lymphoma Clin Cancer Res. 11 5748 55 10.1158/1078-0432.CCR-04-2514
14. A Zettl SL Lee T Rüdiger P Starostik M Marino T Kirchner 2002 Ebstein-Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified Am J Clin Pathol. 117 368 79 10.1309/6UTX-GVC0-12ND-JJEU
15. RC Hawley M Cankovic RJ Zarbo 2006 Angioimmunoblastic T-cell lymphoma with supervening Ebstein-Barr virus-Associated Large B-cell Lymphoma Arch Pathol Lab Med. 130 1707 11
16. K Tobinai T Ohtsu M Hayashi T Kinoshita Y Matsuno K Mukai 1991 Ebstein-Barr virus (EBV) genome carrying monoclonal B-cell lymphoma in a patient with adult T-cell leukaemia-lymphoma Leuk Res. 15 837 46 10.1016/0145-2126(91) 90468-9
17. F Luzzatto G Pruneri E Benini M Manzotti D Laszlo G Martinelli 2005 Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centers and a high content of EBV-infected large B-cells carrying IgH chain gene monoclonal rearrangement Histopathology. 46 464 6 10.1111/j.1365-2559.2004.01997.x
18. J Lundin E Kimby M Bjoerkholm PA Broliden F Celsing V Hjalmar 2002 Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukaemia (B-CLL) Blood. 100 768 73 10.1182/blood-2002-01-0159
19. MJ Keating I Flinn V Jain JL Binet P Hillmen J Byrd 2002 Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study Blood. 99 3554 61 10.1182/blood.V99.10.3554
20. CE Dearden E Matutes B Cazin GE Tjonnfjord A Parreira B Nomdedeu 2001 High remission rate in T-cell prolymphocytic leukaemia with CAMPATH-1H Blood. 98 1721 6 10.1182/blood.V98.6.1721
21. J Lundin H Hagberg R Repp E Cavallin-Stahl S Freden G Juliusson 2003 Phase 2 study of alemtuzumab (anti-CD52 antibody) in patients with advanced mycosis fungoides/Szezary syndrome Blood. 101 4267 72 10.1182/blood-2002-09-2802
22. G Enblad H Hagberg M Erlanson Lundin J Porwit A MacDonald R Repp J Schetelig G Seipelt A Oesterborg 2004 A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy refractory peripheral T-cell lymphomas Blood. 103 2920 4 10.1182/blood-2003-10- 3389
23. J Lundin A Porwit-McDonald ED Rossmann C Karlsson P Edman MR Rezvany 2004 Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia Leukemia. 18 484 90 10.1038/sj.leu.2403258
24. DD Nguyen TM Cao K Dugan SA Starcher RL Fechter SE Coutre 2002 Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukaemia and prolymphocytic leukaemia Clin Lymphoma. 3 105 10
25. L Laurenti P Piccioni P Cattani A Cingolani D Efremov P Chiusolo 2004 Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukaemia.: incidence and treatment with oral ganciclovir Haematologica. 89 1248 52
26. DS Gibbs D Westerman C McCormack JF Sexymour HM Prince 2005 Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders Br J Haematol. 130 87 91 10.1111/j.1365-2141.2005. 05570.x
27. KA Thursky LJ Worth JF Seymour HM Prince MA Slavin 2005 Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab Br J Haematol. 132 3 12 10.1111/j.1365-2141.2005.05789.x
28. Nosari A, Tedeschi A, Ricci F, Montillo M. Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab. Haematologica. 2008;93:e30-1 (online only).
29. AY Peleg S Husain EJ Kwak FP Silveira M Ndirangu J Tran 2007 Opportunistic Infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD52 antibody Clin Infect Dis. 44 204 12 10.1086/510388
30. KR Rai CE Freter RJ Mercier MR Cooper BS Mitchell EA Stadtmauer 2002 Alemtuzumab in previously treated chronic lymphocytic leukaemia patients who also had received fludarabine J Clin Oncol. 20 3891 7 10.1200/JCO.2002.06.119
31. IM Ghobrial LA Otteman 2003 An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab N Engl J Med. 349 2570 1 10.1056/ NEJM200312253492622
32. K Sebelin-Wulf TD Nguyen S Oertel M Papp-Vary RU Trappe A Schulzki 2007 Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD Transpl Immunol. 17 203 10 10.1016/j.trim.2006.10.006
33. AD Kirk WS Cherikh M Ring G Burke D Kaufman SJ Knechtle 2007 Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab Am J Transplant. 7 2619 25 10.1111/j.1600-6143.2007.01972.x
34. LV Abruzzo CM Rosales LJ Medeiros F Vega R Luthra JT Manning 2002 Ebstein-Barr virus-positive lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms Am J Surg Pathol. 26 630 6 10.1097/00000478-200205000-00009
35. N Milpied B Vasseur N Parquet JL Garnier C Antoine P Quartier 2000 Humanized anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients Ann Oncol 11 Suppl1 113 6 10.1023/A:1008372814223
36. I Kuehnle MH Huls Z Liu M Semmelmann RA Krance MK Brenner 2000 CD20 monoclonal antibody (rituximab) for therapy of Ebstein-Barr virus lymphoma after hematopoietic stem-cell transplantation Blood. 95 1502 5
37. HJ Wagner YC Cheng MH Huls AP Gee I Kuehnle RA Krance 2004 Prompt versus preemptive intervention for EBV lymphoproliferative disease Blood. 103 3979 81 10.1182/blood-2003-12-4287
38. P Comoli S Basso M Zecca D Pagliara F Baldanti ME Bernardo 2007 Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation Am J Transplant. 7 1648 55 10.1111/j.1600-6143.2007.01823.x
39. Kluin-Nelemans HC, Coenen JL, Boers JE, van Imhoff GW, Rosati S. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood. 2008 (epub ahead of print).